Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience
A new plain language summary of publication published in Future Cardiology summarises some of the results of a study called ATTR-ACT. The article looked at the participants of the study who took placebo to learn how transthyretin amyloid cardiomyopathy progressed without treatment.
Read the article in full here.
Click here to read the original article on which this summary is based.
The latest plain language summary published in Future Cardiology summarizes an article originally published in Sleep Medicine. The article looks at the levels of sodium in sodium oxybate, a medication for people with narcolepsy, and whether there is any risk of cardiovascular problems as a result of taking the treatment.
Read the full article here.
The original article on which this summary is based is called ‘The sodium in sodium oxybate: is there cause for concern?’ and was originally published in the journal Sleep Medicine. The original article can be read here.
This plain language summary describes the results of a study called ATTR-ACT, which was published in the American Journal of Cardiology. In ATTR-ACT, researchers looked at the effects of tafamidis treatment in people with transthyretin amyloid cardiomyopathy. This summary is intended to help people with ATTR-CM and caregivers understand the disease, its treatment, and results
from ATTR-ACT.
Read the full article here.
The original article, called ‘Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)’ was published in the American Journal of Cardiology and can be read here.
The EXPLORER-HCM trial, originally published in The Lancet, looked at the role of mavacamten as a potential treatment for hypertrophic cardiomyopathy. Wanting to help patients and other non-specialists understand this study, the authors have developed a plain language summary of the publication.
Written by Cynthia Burstein Waldman (a patient author) and Anjali Owens, this new article called ‘A plain language summary of the EXPLORER-HCM study: mavacamten for obstructive hypertrophic cardiomyopathy’ has been published in Future Cardiology.
Read the article in full here.
The original article, entitled ‘Mavacamten for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial’, published in The Lancet, can be found here.